Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Real-time Quote. Real-time Tradegate - 08/29 04:49:05 pm
73.365 EUR   +2.40%
04:23p DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendmen..
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on UCB SA
04:23p DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
08/19 UCB : Transparency notification
08/18 UCB : Transparency notification
08/14 UCB : U.S. District Court confirms validity of patent for UCB's Vimpat®
08/05 AMPHASTAR PHARMACEUTICALS : Purchases International Medication Systems (UK) Limi..
07/28 UCB : continues to deliver on its growth strategy
07/25 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
07/05 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
07/04 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
06/10 UCB : bimekizumab demonstrates positive results in early development in patients..
06/08 UCB : commitment to addressing real world patient needs on display at the Annual..
05/31 UCB : BRIVIACT® now available in U.S. pharmacies for epilepsy patients living wi..
05/19 UCB : Patent Issued for Systems for Automatically Administering Medication (USPT..
05/02 UCB FIRST THREE MONTHS INTERIM REPOR :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
04/28 UCB : shareholder meeting today
04/25 UCB FIRST THREE MONTHS INTERIM REPOR :
04/21 UCB : Patent Issued for Protein Purification (USPTO 9309280)
04/21 UCB : Patent Issued for Chiral Intermediate, Process for Producing the Same and ..
04/14 UCB : Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab Wit..
04/04 AMGEN : and UCB present positive data at ENDO 2016 comparing romosozumab with te..
04/04 UCB : Acquisition of own shares April 1, 2016
04/01 UCB : Amgen and UCB present positive data at ENDO 2016  comparing romosozumab wi..
04/01 UCB : Acquisition of own shares March 1, 2016
03/31 UCB : Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evalua..
03/28 UCB : Nominations for new members of UCB's Board of Directors
03/25 UCB : Convening notice to attend the general meeting of shareholders
03/25 UCB : Nominations for new members of UCB's Board of Directors
03/24 UCB : Announces Results from First Head-to-Head study of Cimzia® (certolizumab p..
03/21 UCB : and Amgen announce positive topline results from phase 3 study evaluating ..
03/19 GLENMARK PHARMACEUTICALS : Wins usfda nod for epilepsy drug
03/07 Pharma crusader takes India's drug regulators to court
02/26 UCB : with progress on its growth path delivering value to patients and sharehol..
02/22 UCB : And Amgen Announce Positive Topline Results From The Phase 3 Study Of Romo..
02/10 UCB : Enters into Research Agreement with Baylor College of Medicine
02/09 UCB : and Baylor College of Medicine launch strategic alliance in neurodegenerat..
02/01 UCB : Executive Committee welcomes a new member
02/01 UCB : new epilepsy drug BRIVIACT® receives EU approval
02/01 UCB : Transparency notification
01/11 UCB : Transparency notification
2015 UCB : New Findings from UCB Pharma SA in the Area of Economic Dynamics Described..
2015 UCB : Transparency notification from BlackRock Inc
2015 LANNETT : Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23..
2015 UCB : Acquisition of own shares
2015 UCB : Transparency notification of The Capital Group Companies, Inc
2015 UCB : Acquisition of Own Shares
2015 AMGEN : UCB -New Exploratory Analysis Showed Romosozumab Increased Estimated Bon..
2015 UCB : Acquisition of own shares (October 9, 2015)
2015 LANNETT : Princeton drugmaker fetches $1.23B in sale
2015 LANNETT : Drug maker Lannett to buy UCB unit for $1.23 bn
2015 LANNETT : UCB to sell its U.S. specialty generics business Kremers Urban to Lann..
2015 Lannett to buy UCB unit to boost speciality generic drugs portfolio
2015DJLANNETT : to Acquire UCB's Kremers Urban Unit
2015 UCB : ex-dividend day for annual dividend
2015 UCB : Convening notice to attend the general meeting of shareholders
2014DJUCB : Advent, Avista End Acquisition Agreement
2014 UCB : Transparency notification of Vanguard Health Care Fund
2014 UCB : Belgium's UCB to sell generics unit for 964 million pounds
2014 EXCLUSIVE- ADVENT, AVISTA NEAR DEAL : sources
2014UCB SA : quaterly earnings release
2014 Pending 'inversions' that new U.S. Treasury rules may hit
2014 Eastman Chemical to buy Taminco for $1.8 bln
2014 EXCLUSIVE : Belgium's UCB explores sale of generics unit Kremers Urban - sources
2014 UCB : Expands Access to Clinical Study Data (Transparency and Sharing)
2014 Pfizer's need for deal looms larger with earnings report
2014 UCB : ex-dividend day for annual dividend
2014 UCB : shareholder meeting today
2014 UCB INTERIM REPORT FOR FIRST THREE M : with a good start into 2014 (UCB Interim ..
2014UCB SA : quaterly earnings release
2014 UCB : Convening notice to attend the annual general meeting of shareholders
2014 UCB : returns global rights to tozadenant to Biotie
2014DJSANOFI : Sanofi, UCB to Seek Anti-Inflammatory Small Molecules
2014DJSANOFI : Sanofi, UCB to Seek Anti-Inflammatory Small Molecules
2014 UCB : Transparency notification of Vanguard Health Care Fund
1  2  3  4  5Next
Advertisement
Financials (€)
Sales 2016 4 047 M
EBIT 2016 736 M
Net income 2016 458 M
Debt 2016 992 M
Yield 2016 1,73%
P/E ratio 2016 28,48
P/E ratio 2017 23,01
EV / Sales 2016 3,77x
EV / Sales 2017 3,44x
Capitalization 14 253 M
More Financials
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 17
Average target price 78,8 €
Spread / Average Target 7,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA-15.84%15 957
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
More Results